2Piedbiois P,Michiels S.Survival benefit of 5Fu/LV over 5-FU bolus in patients with advanced colorectal cancer:An updated meta-analysis based on 2751 patients[J]. Poc Am Soc Clin Oncol,2003,22(3):1180a.
3Rothenberg ML,Oza AM,Burger B,et al. Final results of a phase Ⅲ trial of 5-FU/leucovorin Versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan,5-FU,and leucovorin[J]. Proc Am Soc Clin Oncol,2003,22(3):1011a.
4De Gramont A,Banzi M,Navarro,et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer:Result of the international randomized MOSAIC trial[J]. Proc Am Soc Clin Oncol,2003,22(3):1015a.
6Schuller J,Cassidy J,Dumont E et al.Preferential activation of capecitabin in tumor following oral administration to colonrectal cancer patients.Cancer Chemother Pharmacol,2000,45(4):291
7Fischel JL,Formento P.Impact of the oxaliplatin 5-fluorouracil folinicacid combination on respective intracellular determinants of drug activity.Br J Cancer,2002,86(7):1162
8Johannes Schüller,Jim Cassidy,Etienne Dumont,Brigitte Roos,Sarah Durston,Ludger Banken,Masahiro Utoh,Kazushige Mori,Erhard Weidekamm,Bruno Reigner. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[J] 2000,Cancer Chemotherapy and Pharmacology(4):291～297
1Cunningham Md D,Rao S,Starling N,et al.Randomized multieentre phaseⅢ study comparing capeeitabine with tluorouracil and 0xaliplatin with eisplatin in patients with advanced oesophagogastrie(OG)cancer:The REAL 2 trial[J].Proc Am Soe Clin Oncol,2006,24:4017a.
4Hiromichi Ebi,Yasushi Sigeoka,Toshiaki Saeki,Kenji Kawada,Tadahiko Igarashi,Noriko Usubuchi,Ryuzo Ueda,Yasutsuna Sasaki,Hironobu Minami.Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5′-deoxy-5-fluorouridine (5′-DFUR)[J].Cancer Chemotherapy and Pharmacology.2005(2)
5Johannes Schüller,Jim Cassidy,Etienne Dumont,Brigitte Roos,Sarah Durston,Ludger Banken,Masahiro Utoh,Kazushige Mori,Erhard Weidekamm,Bruno Reigner.Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients[J].Cancer Chemotherapy and Pharmacology.2000(4)
6M Miwa,M Ura,M Nishida,N Sawada,T Ishikawa,K Mori,N Shimma,I Umeda,H Ishitsuka.Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue[J].European Journal of Cancer.1998(8)
7Daniel I. Obrand M.D.,Philip H. Gordon M.D.Incidence and patterns of recurrence following curative resection for colorectal carcinoma[J].Diseases of the Colon & Rectum.1997(1)
